Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
16–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\- Participants who have completed Study M16-067 and have achieved clinical response as defined in the protocol.
You may not be if
Participants who have a known hypersensitivity to risankizumab or the excipients of any of the study drugs or the ingredients of chinese hamster ovary (CHO) or had an adverse event (AE) during Studies M16-067 that in the Investigator's judgment makes the participant unsuitable for this study.
Participant is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
Participant is not in compliance with prior and concomitant medication requirements throughout Studies M16-067.
